CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Sold by BNP Paribas Financial Markets

BNP Paribas Financial Markets cut its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 35.5% during the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 87,956 shares of the company's stock after selling 48,467 shares during the period. BNP Paribas Financial Markets owned 0.10% of CRISPR Therapeutics worth $4,132,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of CRSP. SFE Investment Counsel lifted its position in shares of CRISPR Therapeutics by 3.6% during the second quarter. SFE Investment Counsel now owns 5,846 shares of the company's stock valued at $316,000 after buying an additional 203 shares during the last quarter. Northwestern Mutual Wealth Management Co. raised its stake in shares of CRISPR Therapeutics by 4.8% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 4,606 shares of the company's stock worth $249,000 after acquiring an additional 211 shares in the last quarter. Boston Family Office LLC lifted its position in CRISPR Therapeutics by 2.2% during the third quarter. Boston Family Office LLC now owns 9,763 shares of the company's stock valued at $459,000 after acquiring an additional 213 shares during the last quarter. Bedell Frazier Investment Counselling LLC grew its holdings in CRISPR Therapeutics by 0.8% in the third quarter. Bedell Frazier Investment Counselling LLC now owns 26,357 shares of the company's stock worth $1,238,000 after purchasing an additional 218 shares during the last quarter. Finally, National Bank of Canada FI increased its position in shares of CRISPR Therapeutics by 35.0% during the second quarter. National Bank of Canada FI now owns 848 shares of the company's stock worth $46,000 after purchasing an additional 220 shares in the last quarter. 69.20% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

CRSP has been the subject of a number of recent analyst reports. Barclays lowered their price objective on CRISPR Therapeutics from $59.00 to $55.00 and set an "equal weight" rating for the company in a research report on Wednesday, November 6th. StockNews.com upgraded shares of CRISPR Therapeutics to a "sell" rating in a report on Thursday, November 7th. Truist Financial lowered their target price on shares of CRISPR Therapeutics from $120.00 to $100.00 and set a "buy" rating for the company in a research note on Monday, August 12th. Needham & Company LLC restated a "buy" rating and set a $84.00 price target on shares of CRISPR Therapeutics in a research note on Wednesday, November 6th. Finally, Cantor Fitzgerald reiterated a "neutral" rating on shares of CRISPR Therapeutics in a research note on Thursday, August 8th. Three analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus price target of $74.94.

Insider Activity at CRISPR Therapeutics

In other news, CEO Samarth Kulkarni sold 4,293 shares of the firm's stock in a transaction that occurred on Monday, October 14th. The stock was sold at an average price of $46.28, for a total value of $198,680.04. Following the transaction, the chief executive officer now owns 226,540 shares in the company, valued at $10,484,271.20. This trade represents a 1.86 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, General Counsel James R. Kasinger sold 1,089 shares of the business's stock in a transaction that occurred on Monday, October 14th. The stock was sold at an average price of $46.28, for a total value of $50,398.92. Following the sale, the general counsel now owns 62,597 shares of the company's stock, valued at $2,896,989.16. The trade was a 1.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 50,382 shares of company stock valued at $2,744,179. 4.10% of the stock is owned by company insiders.

CRISPR Therapeutics Trading Down 3.2 %

Shares of CRISPR Therapeutics stock traded down $1.63 during trading hours on Thursday, reaching $49.51. The stock had a trading volume of 1,441,622 shares, compared to its average volume of 1,495,792. The stock's 50 day moving average is $48.56 and its 200 day moving average is $51.53. CRISPR Therapeutics AG has a twelve month low of $43.42 and a twelve month high of $91.10. The firm has a market capitalization of $4.23 billion, a PE ratio of -17.49 and a beta of 1.62.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($1.01) earnings per share for the quarter, topping analysts' consensus estimates of ($1.42) by $0.41. CRISPR Therapeutics had a negative return on equity of 12.15% and a negative net margin of 118.13%. The company had revenue of $0.60 million during the quarter, compared to analysts' expectations of $6.65 million. During the same quarter in the prior year, the firm posted ($1.41) EPS. As a group, sell-side analysts predict that CRISPR Therapeutics AG will post -5.14 earnings per share for the current year.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.